> Biogen paid Neurimmune $50 million (€42 million) to cut the royalty rate on potential future sales of Alzheimer’s candidate aducanumab by 5%. The transaction gives Swiss biotech Neurimmune a one-time cash boost today in exchange for less cash in the future if aducanumab bucks the odds and delivers positive data in phase 3. Statement
> C4X Discovery and e-Therapeutics teamed up to research novel ways to treat Parkinson’s disease. The collaboration builds on C4X’s work to identify genes associated with the disease. Release
> Orchard Therapeutics received a rare pediatric disease designation from the FDA. The status covers the gene therapy specialist’s treatment of metachromatic leukodystrophy. Statement
> A-Mansia raised €13 million ($16 million). The first close of the series A round equips the Belgian microbiome startup to research active components isolated from the Akkermansia muciniphila bacterium. Release
> Oncology Venture, which recently picked up a drug from Novartis, agreed to merge with Medical Prognosis Institute. Statement
> Glialign received seed funding to research a cell therapy for peripheral nerve repair. The UCL Technology Fund contributed to the financing. Release